Advanced BioScience Laboratories, Inc. (ABL) has been selected by PATH, a nonprofit global health organization, for the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable production process under cGMP to produce toxicology and Phase I clinical supply at its facility in Rockville, MD.
The vaccine candidate is based on an IpaB/IpaD fusion protein technology developed by Dr. Wendy Picking at the Department of Microbiology and Molecular Genetics, Oklahoma State University. The IpaB and IpaD proteins are highly conserved within Shigella and are expected to stimulate broad protective immune responses.
Dr. Thomas VanCott, president and chief executive officer of ABL, said, “We are very pleased to have been chosen by PATH to be the contract manufacturer for this important vaccine candidate. Our expertise in the areas of cGMP manufacturing, assay development, and project management combine to provide a unique and comprehensive service for vaccine development from early-stage discovery to clinical trials.”